Pharmacological interventions for clozapine-induced hypersalivation.
Syed Sheriff
Rebecca J
RJ
Health Services and Population Research Department, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK. rebecca.syed@iop.kcl.ac.uk
Au
Katie
K
Cahill
Caroline
C
Duggan
Lorna
L
He
Yanling
Y
Udu
Victor
V
Xia
Jun
J
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016589:Astemizole / Q000627:therapeutic use; D002681:China; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D004316:Doxepin / Q000627:therapeutic use; D006633:Histamine Antagonists / Q000627:therapeutic use*; D006801:Humans; D008516:Medicine, Chinese Traditional; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D015990:Placebo Effect; D011413:Propantheline / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000592:standards / Q000706:statistics & numerical data*; D012798:Sialorrhea / Q000139:chemically induced* / Q000188:drug therapy*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D006633:Histamine Antagonists; D018727:Muscarinic Antagonists; D011413:Propantheline; D004316:Doxepin; D016589:Astemizole; D003024:Clozapine